NCT02850627 is a Phase 4 clinical trial of Tongguan capsule in Coronary Heart Disease, sponsored by Guangdong Provincial Hospital of Traditional Chinese Medicine.

Who is sponsoring NCT02850627?

NCT02850627 is sponsored by Guangdong Provincial Hospital of Traditional Chinese Medicine.

What drugs are being tested in NCT02850627?

Interventions in NCT02850627: Tongguan capsule, placebo capsule.

What condition does NCT02850627 study?

NCT02850627 studies Coronary Heart Disease, Acute Myocardial Infarction.

Is NCT02850627 still recruiting?

NCT02850627 is currently status unknown. Last updated 31 July 2016.

Last reviewed 2016-07-31 · How we verify

NCT02850627

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Effect of Tongguan Capsule for MicroRNA Profiles Between Qi-Stagnation and Qi-Deficiency in Coronary Heart Disease Patients With Blood Stasis Syndrome Undergoing Percutaneous Coronary Intervention

Status unknown Phase 4 Last updated 31 July 2016

What this trial tests

Phase 4 trial testing Tongguan capsule in Coronary Heart Disease in 100 participants. Status unknown.

Timeline

1 July 2016

Primary endpoint
1 September 2017

1 December 2017

Quick facts

Lead sponsor	Guangdong Provincial Hospital of Traditional Chinese Medicine
Phase	Phase 4
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	prevention
Enrollment	100
Start date	1 July 2016
Primary completion	1 September 2017
Estimated completion	1 December 2017
Sites	1 location across China

Drugs / interventions tested

Tongguan capsule — full drug profile →
placebo capsule

Conditions studied

Coronary Heart Disease — all drugs for Coronary Heart Disease →
Acute Myocardial Infarction — all drugs for Acute Myocardial Infarction →

Sponsor

Guangdong Provincial Hospital of Traditional Chinese Medicine

Who can join

Adults 35 to 75, any sex, with Coronary Heart Disease or Acute Myocardial Infarction. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

miRNAs spectrum
Time frame: six months
Test the expression of microRNAs related to the syndromes after the intervention of Tongguan capsule,preliminarily to investigate the mechanism of the effects of Tongguan capsule, and provide the biological foundation of curative effect of Tongguan capsule.

Sponsor's own description

The purpose of this study is to test the expression of microRNAs related to the syndromes after the intervention of Tongguan capsule,preliminarily to investigate the mechanism of the effects of Tongguan capsule, and provide the biological foundation of curative effect of Tongguan capsule.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Implication of microRNA as a potential biomarker of myocarditis.
Oh JH, Kim GB, Seok H. · · 2022 · cited 10× · PMID 35240034 · DOI 10.3345/cep.2021.01802
Micro-RNAs as promising biomarkers in cardiac diseases.
Akodad M, Mericskay M, Roubille F. · · 2016 · cited 7× · PMID 28149912 · DOI 10.21037/atm.2016.12.38
Natural Bioproducts with Epigenetic Properties for Treating Cardiovascular Disorders.
Martínez-Iglesias O, Naidoo V, Carrera I, Corzo L, et al · · 2025 · cited 2× · PMID 40428388 · DOI 10.3390/genes16050566

Verify or expand the search:

Other recruiting trials for Coronary Heart Disease

Currently open trials in the same condition.

NCT07493603 — A Study on Yiyang Huoluo Decoction in the Treatment of Coronary Heart Disease · Phase 1, PHASE2 · recruiting
NCT07230847 — A Study Evaluating the Vascular Healing and Neointimal Transformation at 1 Month After Implantation of BioFreedom™ Drug- · NA · recruiting
NCT07110415 — Efficacy and Safety Trials of Yangxinshi Tablets in the Treatment of Patients With Coronary Heart Disease Complicated by · Phase 4 · recruiting
NCT07451873 — Glycocalyx and Oxidative Stress in Endothelial Function (Part 2) · recruiting
NCT07118930 — Study of Sivelestat Sodium in OPCABG · Phase 2 · recruiting

Other Guangdong Provincial Hospital of Traditional Chinese Medicine trials

Trials by the same sponsor.

NCT07352137 — Endoscopic Nipple-Sparing Mastectomy (E-NSM) With Immediate Multistage Autologous Fat Grafting(IMAFG) for Total Breast R · NA · enrolling by invitation
NCT06908473 — Tongmai Jiangtang Capsule for Cardiovascular Clinical Outcomes in High-Risk Metabolic Syndrome Patients · Phase 3 · enrolling by invitation
NCT06328153 — Efficacy and Mechanism of FSN Treatment for Senile Knee Osteoarthritis · NA · unknown
NCT06166121 — Study on Hyperlipidemia Combined With Carotid Atherosclerosis With ShenJu Granules · NA · unknown
NCT06001112 — Immediate Analgesic Effects of Cheek Acupuncture for Acute Gouty Arthritis · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02850627 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Guangdong Provincial Hospital of Traditional Chinese Medicine
Last refreshed: 31 July 2016

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02850627.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing